- Conditions
- Hemophilia B
- Interventions
- AAV5-hFIXco-Padua
- Genetic
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 857
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Blood Coagulation Disorders
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 30 Days
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Severe Hemophilia A
- Interventions
- rFVIIIFc
- Biological
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Bentonville, Arkansas • Washington D.C., District of Columbia • Fort Wayne, Indiana + 2 more
- Conditions
- Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF)
- Interventions
- Methotrexate (MTX)
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
- Interventions
- Valoctocogene roxaparvovec
- Biological
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
- Interventions
- PEGASYS, Hydroxyurea, Aspirin
- Drug
- Lead sponsor
- Ronald Hoffman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- fitusiran, Bypassing agents
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more
- Conditions
- Congenital Thrombotic Thrombocytopenic Purpura
- Interventions
- No intervention
- Other
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Houston, Texas
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Methemoglobinemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
- Interventions
- chemotherapy, dapsone, medical chart review, assessment of therapy complications
- Drug · Other · Procedure
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Hemophilia B
- Interventions
- PF-06838435/ fidanacogene elaparvovec
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 16
- States / cities
- San Francisco, California • Aurora, Colorado • Indianapolis, Indiana + 2 more
- Conditions
- Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
- Interventions
- azacitidine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- Mezagitamab, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 25
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
- Conditions
- Immune Thrombocytopenia
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Months to 20 Years
- Enrollment
- 95 participants
- Timeline
- 2019 – 2023
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Not listed
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 114
- States / cities
- Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 111 more
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Polycythemia Vera, Previously Treated Myelodysplastic Syndrome, Primary Myelofibrosis, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Azacitidine, Decitabine, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sonidegib
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Immune Thrombocytopenia
- Interventions
- Acetaminophen and Diphenhydramine Only Product
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bleeding Disorder, Von Willebrand Disease (VWD)
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Blood Coagulation Disorders
- Interventions
- ROTEM sigma
- Device
- Lead sponsor
- Tem Innovations GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Baltimore, Maryland • New York, New York
- Conditions
- Von Willebrand Disease
- Interventions
- Wilate
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Congenital Bleeding Disorder, Haemophilia A
- Interventions
- turoctocog alfa
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Male only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • Torrance, California • Peoria, Illinois + 3 more
- Conditions
- Haemophilia A
- Interventions
- NNC0442-0344 A
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut